Biotherapy for lymphoma

Current Oncology Reports

Volumn 2, Issue 2, 2000, Pages 157-162

  McLaughlin, Peter ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic Lymphocytic Leukemia; Fludarabine; Follicular Lymphoma; Lymphoma; Mantle Cell Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXIMAB; VAP CYCLO PROTOCOL; VAP-CYCLO PROTOCOL; VINCRISTINE;

B CELL LYMPHOMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MALE; PREDNISOLONE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0034156645     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-000-0088-7     Document Type: Article

References (56)

1. McLaughlin P, Grillo-López AJ, Link BK, et al.: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998, 16:2825–2833. The pivotal trial that led to the FDA approval of rituximab treatment. Included are data on pharmacokinetics, reported in more detail by Berinstein et al. [4].
2. Coiffier B, Haioun C, Ketterer N, et al.: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927–1932.
3. Piro LD, White CA, Grillo-López AJ, et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1999, 10:655–661.
4. Berinstein NL, Grillo-López AJ, White CA, et al.: Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol 1998, 9:995–1001.
5. Byrd JC, Grever MR, Davis B, et al.: Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL): a feasible and active regimen [abstract]. Blood 1999, 94(suppl 1):704a.
6. O’Brien SM, Thomas DA, Freireich EJ, et al.: Rituxan has significant activity in patients with CLL [abstract]. Blood 1999, 94(suppl 1):603a.
7. Lundin J, Österborg A, Brittinger G, et al.: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin’s lymphomas: a Phase II multicenter study. J Clin Oncol 1998, 16:3257–3263.
8. Leonard JP, Coleman M, Schuster MW, et al.: Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin’s lymphoma (NHL): phase I/II trial results [abstract]. Blood 1999, 94(suppl 1):92a.
9. Behr TM, Wörmann B, Gramatzki M, et al.: Low-versus highdose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999, 5:3304s-3314s.
10. Amlot PL, Stone MJ, Cunningham D, et al.: A phase I study of an anti-CD22-deglycosylated ricin a chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 1993, 82:2624–2633.
11. Almasri NM, Duque RE, Iturraspe J, et al.: Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992, 40:259–263.
12. Venugopal P, Sivaraman S, Huang X, et al.: Upregulation of CD20 expression in chronic lymphocytic leukemia (CLL) cells by in vitro exposure to cytokines [abstract]. Blood 1998, 92(suppl 1):247a.
13. Treon SP, Shima Y, Preffer FI, et al.: Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy. Semin Oncol 1999, 26(suppl 14):97–106. One of several emerging reports indicating that CD20 expression can be influenced by cytokines.
14. Reff ME, Carner K, Chambers KS, et al.: Depletion of B cells in vivo by a chimeric mouse human nonoclonal antibody to CD20. Blood 1994; 83:435–445.
15. Flieger D, Beier I, Sauerbruch T, et al.: Mode of action of monoclonal antibody IDEC-C2B8 against CD20 expressing lymphoma cell lines. Eur J Cancer 1999, 35(suppl 5):S57.
16. Demidem A, Lam T, Alas S, et al.: Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997, 12:177–186.
17. Czuczman MS, Grillo-López AJ, White CA, et al.: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999, 17:268–276.
18. Vose JM, Link BK, Grossbard ML, et al.: Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or highgrade non-Hodgkin’s lymphoma (NHL) [abstract]. Blood 1999, 94(suppl 1):89a.
19. Howard O, Gribben J, Neuberg D, et al.: Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma [abstract]. Blood 1999, 94(suppl 1):631a.
20. Czuczman MS, Jonas C, Stephan M, et al.: Pilot study of rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin’s lymphoma [abstract]. Proc ASCO 1999, 18:17a.
21. McLaughlin P, Hagemeister FB, Rodriguez MA, et al.: Safety of fludarabine, mitoxantrone, and dexamethasone (FND) + rituximab in the treatment of stage IV indolent lymphoma [abstract]. Blood 1999, 94(suppl 1):264b.
22. Press OW, Eary JF, Appelbaum FR, et al.: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219–1224. See annotation following [24].
23. Kaminski MS, Zasadny KR, Francis IR, et al.: Radioimmunotherapy of B-cell lymphoma with [1311] anti-B1 (anti-CD20) antibody. N Engl J Med 1993, 329:459–465. See annotation following [24].
24. Kaminski MS, Zasadny KR, Francis IR, et al.: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996, 14:1974–1981. These are some of the key reports on RIT with anti-CD20 antibodies conjugated to 131I, the radioimmunoconjugate for which there is the most clinical experience to date.
25. Press OW: Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999, 26(suppl 14):58–65.
26. Wiseman GA, White CA, Witzig TE, et al.: Radioimmunotherapy of relapsed non-Hodgkin’s lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999, 5:3281s-3286s. Report on another anti-CD20 radioimmunoconjugate that has been studied extensively, including in multicenter trials. In many US states, regulatory and radiation safety constraints are less restrictive for yttrium than for iodine.
27. De Nardo GL, Lamborn KR, Goldstein DS, et al.: Increased survival associated with radiolabeled Lym-1 therapy for non-Hodgkin’s lymphoma ans chronic lymphocytic leukemia. Cancer 1997, 80:2706–2711.
28. O’Donnell RT, De Nardo GL, Kukis DL, et al.: 67Copper-2-Iminothiolane-6-[p-(Bromoacetamido)benzyl]-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin’s lymphoma. Clin Cancer Res 1999, 5:3330s-3336s. Clinical data on another isotope, copper. RIT may become a crowded arena, but we need all the good treatment options we can get.
29. Juweid ME, Stadtmauer E, Hajjar G, et al.: Pharmacokinetics, dosimetry, initial therapeutic results with 131I- and 111In-/ 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin’s lymphoma. Clin Cancer Res 1999, 5:3292s-3303s. Early data on a radioimmunoconjugate using a humanized monoclonal antibody.
30. Blend MJ, Hyun H, Kozlof M, et al.: Improved staging of B-cell non-Hodgkin’s lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res 1995, 55:5764s-5770s.
31. Jiang L, Pan L-Z, Hariharan K, et al.: Enhanced effector function of dimeric forms of IDEC-C2B8 (rituximab) [abstract]. Blood 1999, 94(suppl 1):86a.
32. Shan D, Ledbetter A, Press OW: Apoptosis of malignant human B-cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 9:1644–1652.
33. Dechuant M, Stockmeyer B, Vidarsson G, et al.: Human chimeric IgA antibodies mediate improved effector cell recruitment against B-cell lymphoma [abstract]. Blood 1999, 94(suppl 1):89a.
34. Solal-Céligny P, Lepage E, Brousse N, et al.: Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d’Etude des Lymphomes Folliculaires 86 trial. J Clin Oncol 1998, 16:2332–2338. The most recent update of an important French-Belgian trial, which provides compelling data in favor of using IFN in conjunction with chemotherapy for patients with follicular lymphoma.
35. Smalley R, Weller E, Hawkins M, et al.: Alpha interferon in non-Hodgkin’s lymphoma: an update of the ECOG I-COPA trial (E6484) [abstract]. Blood 1998, 92(suppl 1):486a.
36. McLaughlin P: The role of interferon in the therapy of malignant lymphoma. Biomed Pharmacother 1996, 50:140–148.
37. Verstovsek S, Romaguera JE, Cabanillas F, et al.: CHOP-Bleo plus interferon-a for stage IV low grade lymphoma: an update after 13-year follow up: significant improvement in both overall and failure-free survival [abstract]. Blood 1999, 94(suppl 1):270b.
38. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 1993, 20:75–88.
39. van Besien K, Sobocinski KA, Rowlings PA, et al.: Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998, 92:1832–1836.
40. Khouri IF, Keating M, Körbling M, et al.: Transplant-lite: Induction of graft-versus-malignancy using fludarabinebased nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817–2824. A "transplant-lite" approach may mean that allogeneic stem cell transplant approaches may be feasible for more (eg, older) patients. Demonstration of the graft-versus-lymphoma effect of donor lymphocyte infusion therapy provides support for allogeneic transplant in particular, and T-cell therapy in general.
41. Schultze JL, Seamon MJ, Michalak S, et al.: Autologous tumor infiltrating T cell cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood 1997, 89:3806–3816.
42. Kwak LW, Campbell MJ, Czerwinski DK, et al.: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med 1992, 327:1209–1215.
43. Hsu FS, Benike C, Fagroni F, et al.: Vaccination of patient with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52–58.
44. Bendandi M, Gocke CD, Kobrin CB, et al.: Complete molecular remission induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999, 5:1171–1177. A well thought out integration of a vaccine strategy into front-line therapy.
45. King CA, Spellerberg MB, Zhu D, et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat Med 1998, 4:1281–1286. This report represents an innovative step in the field of DNA vaccines. Similar approaches should become increasingly feasible as we identify the peptides and genes of interest as targets for vaccine development.
46. Ménoret A, Chandawarkar R: Heat-shock protein-based anticancer immunotherapy: an idea whose time has come. Semin Oncol 1998, 25:654–660.
47. Krieg AM, Ballas ZK, Hartmann G, et al.: Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy [abstract]. Eur J Cancer 1999, 35(suppl 5):s10.
48. Hart DNJ, Schultze JL, Stewart AK: Presentation of tumor antigens. Semin Hematol 1999, 36(suppl 3):21–25.
49. Lyman SD, Jacobsen SEW: c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998, 91:1101–1134.
50. Jansen B, Schlagbauer-Wadl H, Brown BD, et al.: bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 1998, 4:232–234.
51. Tormo M, Tari AM, McDonnell TJ, et al.: Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation. Leuk Lymphoma 1998, 30:367–379.
52. Cotter FE: Antisense therapy of hematologic malignancies. Semin Oncol 1999, 36(suppl 6):9–14.
53. French RR, Chan HT, Tutt AL, Glennie MJ.: CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999, 5:548–553.
54. Raiter A, Novogrodsky A, Hardy B: Activation of lymphocytes by BAT and anti-CTLA-4: comparison of binding to T- and B cells. Immunol Lett 1999, 69:247–251.
55. Ribeiro P, Renard N, Warzocha K, et al.: CD40 regulation of death domains containing receptors and their ligands on lymphoma B cells. Br J Haematol 1998, 103:684–689.
56. Ghia P, Boussiotis VA, Schultze JL, et al.: Unbalanced expression of Bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signaling in promoting survival. Blood 1998, 91:244–251.